ADA Scientific Sessions 2026 Abstract
BGE-102, a Novel NLRP3 Inhibitor, Demonstrated Robust Anti-Inflammatory Activity in an Ongoing Phase 1 Study in Healthy Volunteers and Participants with Obesity
Trial in peopleInterventions
Papers by Eric Morgen
3 results
- ADA Scientific Sessions 2025 Abstract
The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction
Experiments in animalsInterventions - ADA Scientific Sessions 2025 Abstract
The Oral Apelin Receptor Agonist Azelaprag Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide
Experiments in animalsInterventions